nad has been researched along with 1,2-dihydro-1-hydroxy-6-methyl-2-(propanesulfonyl)-thieno(3,2d)(1,2,3)-diazaborine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bergler, H; Fuchsbichler, S; Högenauer, G; Turnowsky, F | 1 |
1 other study(ies) available for nad and 1,2-dihydro-1-hydroxy-6-methyl-2-(propanesulfonyl)-thieno(3,2d)(1,2,3)-diazaborine
Article | Year |
---|---|
The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
Topics: Anti-Bacterial Agents; Boron Compounds; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Enzyme Inhibitors; Escherichia coli; Escherichia coli Proteins; Fatty Acid Synthase, Type II; Fatty Acid Synthases; Molecular Weight; NAD; NADP; Oxidoreductases; Palmitoyl Coenzyme A | 1996 |